Table 3.
Relative risk estimates of PD for the levels of PBL NURR1 gene expression
| PD-OR | Non-MDC-OR | MDC-OR | ||||||
|---|---|---|---|---|---|---|---|---|
| Risk estimate in HC and PD groups | Risk estimate in HC and NDC groups | Risk estimate in HC and NDC groups | ||||||
| OR (95% CI) | OR (95% CI) | OR (95% CI) | ||||||
| Overall: | Overall: | Overall: | ||||||
| 1.66 (1.02–2.10) | <0.001 | NS | NS | |||||
| Gender | Gender | Gender | ||||||
| Male | 1.44 (0.99–1.89) | <0.05 | Male | NS | Male | NS | ||
| Female | 1.78 (1.01–2.16) | <0.01 | Female | NS | Female | NS | ||
| Age | Age | Age | ||||||
| <60y | 1.69 (1.00–2.21) | <0.05 | <60y | NS | <60y | NS | ||
| >=60y | 1.85 (1.00–2.29) | <0.01 | >=60y | NS | >=60y | NS | ||
| Race | Race | Race | ||||||
| Caucasian | 1.56 (1.02–2.10) | <0.001 | Caucasian | NS | Caucasian | NS | ||
| Other | NS | Other | NS | Other | NS | |||
OR = odds ratio; NS = not significant. The relative risks for patients with PD, NDC, non-movement disease controls (Non-MDC), and movement disease controls (MDC) were estimated by OR value in overall sample after adjusted by age, gender and ethnicity.